TITLE

Chiron's manufacturing misfortunes boost competitors

AUTHOR(S)
Sheridan, Cormac
PUB. DATE
October 2005
SOURCE
Nature Biotechnology;Oct2005, Vol. 23 Issue 10, p1191
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on problems faced by Chiron Corp., the world's second largest flu vaccine supplier. Chiron's ongoing problems in influenza vaccine production have raised serious questions about the Emeryville, California company's future ability to compete in this particular segment of the vaccine market. And with Basel-based Novartis' recent bid for the Chiron shares it doesn't already own, the future of one of biotech's oldest companies as an independent firm is in jeopardy. Chiron's recently and expensively acquired position as the world's second largest flu vaccine supplier is now under threat; particularly as rivals London-based GSK and Vancouver-based ID Biomedical Corp., who are already ramping up output significantly, in Germany and in Canada, respectively, may now merge.
ACCESSION #
18506830

 

Related Articles

  • GSK catches flu shot.  // Chemical Market Reporter;9/12/2005, Vol. 268 Issue 8, p5 

    Reports that United States-based pharmaceutical firm Glaxosmithkline PLC continued its aggressive pursuit of a top slot in the flu vaccines arena with its bid for Vancouver, British Columbia-based ID Biomedical Corp. Worth of the bid; Benefit of the acquisition to Glaxosmithkline;...

  • Industry News Headlines April 15, 2004 - May 14, 2004.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p20 

    Reports developments in the biotechnology industry as of April 2004. Acquisition of Shire Pharmaceuticals by ID Biomedical Corp.; Details on the lawsuit filed by Biota against GlaxoSmithKline PLC for failure to promote influenza drug; Sale of Zonegran, an ani-epiletic drug to Eisai Inc.

  • EXPANDED HUMAN TESTING OF NASAL FLU VACCINE BEGINS.  // Worldwide Biotech;Jul2001, Vol. 13 Issue 7, p2 

    Announces the start of the expanded human safety and immunogenecity testing of the intranasal influenza vaccine from ID Biomedical Corporation.

  • A Shot in the Arm. Kher, Unmesh // Time;1/9/2006, Vol. 167 Issue 2, pA4 

    The article reports on Novartis's planned acquisition of the troubled drug company Chiron. Chiron was partially responsible for the 2004 flu-vaccine shortage, begun when the company dumped 48 million doses of the vaccine due to contamination. Chiron's stock fell and the company was having...

  • Vaccine Manufacturer Expecting Delays in Distribution of Fluvirin. Ressel, Genevieve // American Family Physician;10/15/2004, Vol. 70 Issue 8, p1433 

    Reports that Chiron Corp., the manufacturer of the influenza virus vaccine Fluvirin, are expecting delays in distribution of the vaccine. Reason behind the delay; Estimated schedule of shipping of the vaccine.

  • 'Vaccine shortage averted'  // Pulse;7/23/2005, Vol. 65 Issue 29, p7 

    Reports that Chiron Corp. has reassured general practitioners (GP) that it will be able to fulfill influenza vaccine orders in Great Britain. Fear of British GP after quality control problems in a vaccine plant in Germany; Mitigation of the impact of shortages of Begrivac; Reallocation of other...

  • Health Officials Brace for Flu Season. Mitka, Mike // JAMA: Journal of the American Medical Association;10/13/2004, Vol. 292 Issue 14, p1670 

    Reports on the unexpected problems that have raised concerns about flu vaccinations in the United States. Question of whether delivery of some vaccine supplies will be delayed; Decision of the Chiron Corp. to delay release of half of its vaccine supply to the U.S. in order to determine the...

  • Canadian company to develop mock pandemic vaccine. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;3/1/2005, Vol. 172 Issue 5, p623 

    Focuses on a mock pandemic vaccine being developed by Vancouver-based ID Biomedical Corp. to protect people against H5N1 influenza in British Columbia. Utilization of reverse genetics technology; Requirements for the phase II clinical trials; Comment from Michele Roy, spokesperson for ID...

  • Influenza Vaccine 1980-1981.  // Annals of Internal Medicine;Sep80, Vol. 93 Issue 3, p466 

    Presents an annual revision of influenza vaccine recommendations in the U.S. as of 1980. Predominant strain of influenza virus in the U.S. during 1979 to 1980; Subtypes of influenza A on the basis of two antigens; General recommendations for vaccine use; Influenza vaccine available from 1980 to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics